Abstract 12580: Does Sex Influence the Effect of Surgical Revascularization in Patients in Ischemic Left Ventricular Dysfunction? Results From the STICH Trial
Introduction: Studies have shown sex-specific differences regarding CAD and heart failure with left ventricular (LV) dysfunction. Whether these differences impact the benefit of CABG in patients with ischemic LV dysfunction has not been studied prospectively. Female sex is conventionally considered a risk factor for open-heart surgery, and has been included as a poor prognostic factor in multiple cardiac operative risk evaluation scores. We investigated the impact of sex on the long-term benefit of CABG in patients enrolled in the prospective Surgical Treatment for Ischemic Heart Failure Study (STICH) trial.
Method: The STICH trial randomized 1212 patients [148 (12%) women and 1064 (88%) men] with CAD and EF≤ 35% to medical therapy alone (MED) versus MED plus CABG. Long-term (10-year) outcomes with each treatment were compared according to sex.
Results: At baseline, women were older with higher BMI and more CAD risk factors (e.g. diabetes) except for smoking, and had lower rates of prior CABG than men (all p<0.05). Moreover, women had higher NYHA class, lower 6-min walk capacity and lower Kansas City Cardiomyopathy Questionnaire scores (all p<0.05). At 10-year follow up, the all-cause mortality rate (HR 0.70, CI 0.55-0.89, adjusted p=0.002) and CV mortality rate (HR 0.64, CI 0.48-0.86, adjusted p=0.006) were significantly lower in women than men. Furthermore, with randomization to CABG vs. MED treatment, there was no significant interaction between sex and treatment group in all-cause mortality, CV mortality, mortality or CV hospitalization (all p>0.05, Figure 1). In addition, surgical deaths were similar for both sexes among patients randomized to CABG.
Conclusion: Sex does not impact the effect of CABG on all-cause mortality, CV mortality, CV hospitalization or surgical deaths in patients with ischemic LV dysfunction. Thus, sex should not influence treatment decisions regarding CABG in these patients.
Author Disclosures: Q. Zheng: None. N. Cyrille: None. L. She: None. H. Szwed: None. I.M. Lang: None. P.S. Farsky: None. S. Castelvecchio: None. J. Biernat: None. A. Paraforos: None. D. Kosevic: None. L.E. Favaloro: None. J.C. Nicolau: None. P. Varadaragan: None. E. Velazquez: None. R.G. Pai: None. K. Lee: None. P. Desvigne-Nickens: None. I.L. Piña: None.
- © 2016 by American Heart Association, Inc.